SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech binary events -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (136)10/25/2003 5:03:07 AM
From: Icebrg  Read Replies (1) | Respond to of 295
 
CV Therapeutics' Ranexa: Odds For Approval Good'
By Randall Osborne
National Editor

Though still waiting for an action letter from the FDA, CV Therapeutics Inc.'s news Thursday that an advisory panel has slated for Dec. 9 a review of Ranexa (ranolazine) for chronic angina was enough to boost the company's stock....

bioworld.com